<DOC>
	<DOCNO>NCT01926665</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose carfilzomib give patient lymphoma stem cell transplant . The safety drug also study . Carfilzomib design block cancer cell repair . If cancer cell repair , may cause die .</brief_summary>
	<brief_title>Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation ( ASCT ) Mantle Cell Lymphoma ( MCL ) , T-cell Lymphoma ( TCL ) , Diffuse Large B-Cell Lymphoma ( DLBCL )</brief_title>
	<detailed_description>Study Groups : If agree take part study , assign dose level carfilzomib base join study . Up 4 dose level carfilzomib test . Three ( 3 ) participant enrol dose level high tolerable dose level find . Each new group receive high dose group , intolerable side effect see . When high tolerable dose find , participant may enrol dose level . Study Treatment : Each study cycle 28 day . On Days 1 , 2 , 15 , 16 cycle , receive carfilzomib vein 30 minute . You receive hydration vein infusion carfilzomib Cycle 1 . This may repeat Cycle 2 , doctor think need . On day Cycles 1 2 , receive carfilzomib receive dexamethasone vein tablet mouth . Dexamethasone may help prevent possible infusion reaction . You may continue receive dexamethasone dose cycle depend well tolerate infusion . You monitor closely least 1 hour possible infusion reaction dose Cycle 1 Day 1 Cycle 2 . If infusion reaction , doctor may delay stop infusion , may receive drug help relieve symptom . You 12 day `` rest '' cycle treatment ( time receive carfilzomib ) . Study Visits : On Day 1 ( + - 3 day ) Cycle 1 Day 1 cycle , woman able become pregnant blood ( 1 teaspoon ) drawn pregnancy test . To take part study , must pregnant . About 1 day receive carfilzomib cycle : - You physical exam include measurement vital sign ( blood pressure , heart rate , temperature , breathe rate ) . - You ask feel side effect may . About 1 day 15 day receive carfilzomib cycle , blood ( 2 tablespoon ) draw routine test check kidney liver function . At point doctor think need , bone marrow aspiration compute tomography ( CT ) and/or positron emission tomography ( PET ) scan check status disease . To collect bone marrow aspirate , area hip site numb anesthetic , small amount bone marrow withdrawn large needle . End-of-Treatment Visit : Within 30 day last dose study drug , return clinic . The following test procedure perform : - You physical exam , include measurement vital sign . - You ask feel side effect may . - Blood ( 4 tablespoon ) draw routine test check status disease . During follow-up , study staff may also contact local doctor telephone ask health . Length Study : You may remain study 2 year time first dose . You may receive 6 cycle treatment time , take 7 month complete . You take study early disease get bad , keep appointment , miss 2 dos carfilzomib row , intolerable side effect occur , decide want leave study early . This investigational study . Carfilzomib FDA approve commercially available treatment multiple myeloma . The use carfilzomib treat lymphoma stem cell transplant investigational . Up 30 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Patients mantle cell lymphoma , Tcell lymphoma , diffuse large bcell lymphoma within 6 month post autologous transplantation without relapse . 2 . Age &gt; /= 18 year &lt; /= 70 year . 3 . Absolute neutrophil count ( ANC ) &gt; /= 1.5 x 10^9/L ; Platelets &gt; 75 x 10^9/L . 4 . No active infection . 5 . Performance status : Eastern Cooperative Oncology Group ( ECOG ) 2 less Karnofsky least 60 . 6 . Cardiac EF &gt; /= 45 % 2DEcho . 7 . Serum creatinine le 1.6 mg/dl Creatinine Clearance &gt; /= 30 mL/min . 8 . Liver function test less 2x upper limit normal range ( unless relate medication Gilbert 's disease ) . 9 . Females childbearing potential pregnant breastfeeding . 10 . Patient legally authorize representative able sign inform consent . 1 . Glucocorticoid therapy ( prednisone &gt; 30 mg/day equivalent within 14 day first dose . 2 . POEMS syndrome . 3 . Plasma cell leukemia circulate plasma cell &gt; /= 2 X 10^9/L . 4 . Waldenstrom 's Macroglobulinemia . 5 . Patients know amyloidosis . 6 . Immunotherapy chemotherapy approve investigational anticancer therapeutic within 21 day first dose . 7 . Patients previously randomize Onyxsponsored Phase 3 trial . 8 . Active congestive heart failure ( NYHA Class III IV ) , symptomatic ischemia , conduction abnormality uncontrolled conventional intervention . Myocardial infarction within 6 month . 9 . Acute active infection require systemic antibiotic , antiviral ( except antiviral direct Hepatitis B ) antifungal agent within 14 day first dose . 10 . Known HIV seropositive , hepatitis C infection , and/or hepatitis B ( except patient hepatitis B SAg core antibody receive respond antiviral therapy direct hepatitis B : patient allow ) . 11 . Patients know cirrhosis . 12 . Second malignancy within past three year except : a. adequately treat basal squamous cell skin cancer . b. carcinoma situ cervix . c. prostate cancer &lt; Gleason Score 6 stable prostatic specific antigen ( PSA ) past three month . d. breast cancer situ full surgical resection . e. treat medullary papillary thyroid cancer . 13 . Patients myelodysplastic syndrome . 14 . Significant neuropathy ( Grades 3 4 , Grade 2 pain ) . 15 . Known hypersensitivity carfilzomib . 16 . Known contraindication dexamethasone . 17 . Pleural effusion require thoracentesis ascites require paracentesis within 14 day first dose . 18 . Any clinically significant medical disease psychiatric condition , Investigator 's opinion , may interfere protocol compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Blood And Marrow Transplantation</keyword>
	<keyword>Mantle cell lymphoma</keyword>
	<keyword>MCL</keyword>
	<keyword>T-cell lymphoma</keyword>
	<keyword>TCL</keyword>
	<keyword>Diffuse large b-cell lymphoma</keyword>
	<keyword>DLBCL</keyword>
	<keyword>Autologous stem cell transplantation</keyword>
	<keyword>ASCT</keyword>
	<keyword>Carfilzomib</keyword>
	<keyword>CFZ</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Decadron</keyword>
</DOC>